InflaRx reports Phase IIa data of mAb against C5a for rare inflammatory skin disease

In September, InflaRx N.V. (NASDAQ:IFRX) reported data from a Phase IIa trial in 12 patients with moderate to severe hidradenitis suppurativa showing that

Read the full 239 word article

How to gain access

Continue reading with a
two-week free trial.